[go: up one dir, main page]

PE20060554A1 - Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de la fosfotirosina fosfatasa 1b y procedimientos para su preparacion - Google Patents

Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de la fosfotirosina fosfatasa 1b y procedimientos para su preparacion

Info

Publication number
PE20060554A1
PE20060554A1 PE2005000803A PE2005000803A PE20060554A1 PE 20060554 A1 PE20060554 A1 PE 20060554A1 PE 2005000803 A PE2005000803 A PE 2005000803A PE 2005000803 A PE2005000803 A PE 2005000803A PE 20060554 A1 PE20060554 A1 PE 20060554A1
Authority
PE
Peru
Prior art keywords
diphenylamine
phosphatase
preparation
saliciltiazoles
phosphothyrosine
Prior art date
Application number
PE2005000803A
Other languages
English (en)
Inventor
Stefan Petry
Karl-Heinz Baringhaus
Norbert Tennagels
Reinhard Kirsch
Guenter Mueller
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20060554A1 publication Critical patent/PE20060554A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE SALICILTIAZOL DE FORMULA I, DONDE R1, R2, R3, R4 Y R5 SON H, F, OH, CF3, ENTRE OTROS; R6 ES H, ALQUILO C1-C6; A ES UN ENLACE, CH2, NH, S, ENTRE OTROS; B ES NH, NH-ALQUILO C1-C4, NH(CO); D ES FENILO, HETEROCICLO. TAMBIEN ESTA REFERIDA A UN MEDICAMENTO Y A UN PROCEDIMIENTO DE PREPARACION DE DICHO MEDICAMENTO. DICHO COMPUESTO ES INHIBIDOR DE LA FOSFOTIROSINA FOSFATASA 1B Y ES UTIL PARA REDUCIR EL NIVEL DE GLUCOSA EN SANGRE
PE2005000803A 2004-07-17 2005-07-11 Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de la fosfotirosina fosfatasa 1b y procedimientos para su preparacion PE20060554A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004034697A DE102004034697A1 (de) 2004-07-17 2004-07-17 Mit Diphenylamin oder Diphenylaminderivaten substituierte Salicylthiazole, Verfahren zu deren Herstellung und deren Verwendung

Publications (1)

Publication Number Publication Date
PE20060554A1 true PE20060554A1 (es) 2006-06-24

Family

ID=34971604

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000803A PE20060554A1 (es) 2004-07-17 2005-07-11 Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de la fosfotirosina fosfatasa 1b y procedimientos para su preparacion

Country Status (20)

Country Link
US (1) US7741491B2 (es)
EP (1) EP1771426B1 (es)
JP (1) JP2008506643A (es)
KR (1) KR20070043787A (es)
CN (1) CN100582098C (es)
AR (1) AR049588A1 (es)
AT (1) ATE381551T1 (es)
AU (1) AU2005263418A1 (es)
BR (1) BRPI0513423A (es)
CA (1) CA2574162A1 (es)
DE (2) DE102004034697A1 (es)
DK (1) DK1771426T3 (es)
ES (1) ES2296199T3 (es)
IL (1) IL180570A0 (es)
MX (1) MXPA06014443A (es)
PE (1) PE20060554A1 (es)
PT (1) PT1771426E (es)
TW (1) TW200616985A (es)
UY (1) UY29020A1 (es)
WO (1) WO2006007959A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
CA2469228A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
EA008769B1 (ru) * 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета

Also Published As

Publication number Publication date
AU2005263418A1 (en) 2006-01-26
JP2008506643A (ja) 2008-03-06
US20070191441A1 (en) 2007-08-16
CN100582098C (zh) 2010-01-20
HK1104534A1 (en) 2008-01-18
UY29020A1 (es) 2006-02-24
DE502005002310D1 (de) 2008-01-31
ES2296199T3 (es) 2008-04-16
PT1771426E (pt) 2008-01-31
ATE381551T1 (de) 2008-01-15
KR20070043787A (ko) 2007-04-25
WO2006007959A1 (de) 2006-01-26
CA2574162A1 (en) 2006-01-26
EP1771426A1 (de) 2007-04-11
IL180570A0 (en) 2007-06-03
BRPI0513423A (pt) 2008-05-06
CN1989116A (zh) 2007-06-27
DE102004034697A1 (de) 2006-02-09
AR049588A1 (es) 2006-08-16
MXPA06014443A (es) 2007-03-21
TW200616985A (en) 2006-06-01
US7741491B2 (en) 2010-06-22
DK1771426T3 (da) 2008-05-05
EP1771426B1 (de) 2007-12-19

Similar Documents

Publication Publication Date Title
PE20060554A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de la fosfotirosina fosfatasa 1b y procedimientos para su preparacion
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
CO6450621A2 (es) Sulfonamidas nematocidas
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
PE20061073A1 (es) Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
AR078576A1 (es) Amidas y tioamidas de diazol utiles para combatir parasitos animales, en particular insectos y procedimiento para prepararlas.
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
PE20020354A1 (es) Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
PE20090042A1 (es) Analogos de ciclopamina
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
MX2007003636A (es) Composiciones funguicidas.
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
CO6150146A2 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas su preparacion y su aplicacion en terapeutica
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20080843A1 (es) Inhibidores de renina y metodo para su utilizacion
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
WO2007120379A3 (en) Sulfonanilide analogs as selective aromatase modulators

Legal Events

Date Code Title Description
FC Refusal